IVE randomized, double-blind, placebo-controlled trials of tirilazad were conducted between 1990 and 1997. 12,13,18,21,22 These studies focused on a large cohort of patients with aneurysmal SAH who were treated by methods not previously included in similar trials.
consent for participation was obtained. Patients with nonsaccular aneurysms (fusiform, traumatic, or mycotic lesions); severe complicating medical, neurological, or psychiatric illnesses; serious cardiovascular complications; pregnancy or lactation; and/or those receiving steroid medications or calcium-channel blockers were excluded from the studies. In the third and fourth studies, only women were enrolled. This was the only difference in entry criteria among the studies. Patients were randomized to receive vehicle or various doses of tirilazad, which were administered until Day 10 post-SAH (the day of SAH was defined as Day 0). Nimodipine, hemodynamic therapy, and mechanical or pharmacological angioplasty were permitted and used at the discretion of the treating physician, but other experimental therapies, steroid medications, and other calcium-channel antagonists were not. The timing of surgery was decided by the neurosurgeon. Patients were excluded if they underwent Guglielmi Detachable Coil placement in the ruptured aneurysm.
Definition of Vasospasm
Primary and secondary end points for each study varied, but a uniform definition for vasospasm was used. Symptomatic vasospasm was defined by the following clinical criteria: 1) classic symptoms that include onset between Days 5 and 12 post-SAH; worsening headache, stiff neck, and/or low-grade fever; insidious onset of confusion, disorientation, and/or decline in the level of consciousness; and a focal deficit, which may fluctuate in severity; 2) a head CT scan excluding other causes of neurological worsening, such as rebleeding or hydrocephalus; 3) no other identifiable cause of neurological worsening, such as electrolyte disturbance, hypoxia, or seizure; and 4) confirmation of vasospasm by angiography or transcranial Doppler ultrasonography, which was recommended but not required. 14 Neurological worsening was defined as a decrease in the modified GCS score 17 of two points or greater or a twopoint or greater increase in the motor score of the National Institutes of Health Stroke Scale, which lasted for 8 or more hours. 4 When neurological worsening occurred, the treating physician was required to submit standardized study forms in which were defined the criteria met for neurological deterioration, what the primary and secondary causes of the deterioration were, and what investigations were undertaken to determine whether the worsening was due to vasospasm or to some other cause such as infection.
Clinical and Radiological Variables
The clinical variables assessed included the following: patient age, sex, race, history of hypertension, admission neurological grade 10 and modified GCS score, 17 body temperature on admission, and systolic and diastolic blood pressures on admission. Radiological features entered into the analysis were clot thickness measured on the admission CT scan; presence or absence of IVH, ICH, or hydrocephalus; and the location and size of the ruptured aneurysm. Treatments analyzed as present or absent included: whether anticonvulsant medications were given and, if so, whether the drug was carbamazepine, phenobarbital, or phenytoin; whether surgery was performed; and whether the prophylactic or therapeutic administration of hypervolemia, hemodilution, and/or induced hypertension was in use. Indicator variables for the particular study in which the patient was included and the dose of tirilazad (0.6, 2, 6, or 15 mg/kg/ day) that was given also were entered.
The patient' s temperature on admission was entered as a continuous or dichotomized variable based on whether it was higher than 38C or was 38C or lower. Age was entered as a continuous variable or as a categorical variable by decade, except that ages 18 to 29 years were considered as one group because of the small number of patients included in the two decades. Neurological grade was classified by the WFNS scale. 10 Blood pressure values were analyzed as continuous variables or divided into categorical variables of 5-to 20-mm Hg increments depending on the number of patients within each range. The SAH on the admission CT scan was classified by the maximal amount of blood as none, diffuse thin or thick, or localized thin or thick. Intraventricular hemorrhage and ICH were entered as present or absent. Ventricular size was dichotomized into normal or absent, or as small or enlarged (hydrocephalus). The location of the ruptured aneurysm was classified as ICA, ACA, MCA, posterior circulation, or other; and the size of the lesion as 12 mm or smaller, 13 to 24 mm, or 25 mm or larger.
Statistical Analysis
The primary question asked in this study was what fac- tors are associated with the development of vasospasm, which was treated as the dependent variable and as dichotomous (present or absent). Data are given as means Ϯ standard deviations. Variables identified earlier as potentially associated with vasospasm were analyzed using logistic regression models. Log odds were examined to assess the linearity of the effect for continuous variables. On this basis, the patient' s age and temperature on admission were modeled as categorical variables (because the effects were nonlinear) and the blood pressure on admission was modeled as a continuous variable. Statistically significant variables (p Ͻ 0.05) in the simple logistic regressions were entered into multivariate logistic models by using a stepwise backward selection procedure, in which the indicator variable for the study and the dose of tirilazad were forced into the model and the probability value for removal of other variables was set at 0.15. Unadjusted and adjusted ORs and 95% CIs for occurrence of vasospasm were derived from the logistic regression models. Tests for interaction were performed between each variable entered into the multivariate models and the study indicator variable. The reference group for calculation of ORs consisted of men, 18 to 29 years of age, who were in neurological (WFNS) Grade I with no SAH on the admission CT scan and a ruptured aneurysm 12 mm or smaller in size. The reference study group was the vehicle-administered control group in the first tirilazad study conducted in Europe, Australia, and New Zealand. 18 These analyses were performed on the entire database and then repeated separately for the first two studies, 13, 18 the third and fourth studies, in which only women were enrolled, 21, 22 and then again only for patients with WFNS grades between I and III.
Results
The mean age of the 3567 patients was 52 Ϯ 14 years and 83% of them were women ( Table 2) . Thirty-three percent of the patients had a history of hypertension prior to admission. The clinical conditions were predominately good grade, with 36% of patients in WFNS Grade I, 30% in Grade II, 11% in Grade III, 10% in Grade IV, and 13% in Grade V. Thick SAH was observed on the admission CT A univariate analysis of the continuous variables (patient age, systolic and diastolic blood pressure, temperature, and modified GCS score assigned on admission) found a significant relationship between lower GCS score, elevated admission systolic blood pressure, and development of vasospasm. When all factors were entered into a univariate analysis as categorical or dichotomous variables, the incidence of vasospasm displayed a significant inverted U-shaped relationship with age (Table 3) . Patients who were 40 to 59 years of age had the highest risk of vasospasm. Age was not significant when analyzed as a continuous variable because of the nonlinear relationship of age with vasospasm. In addition, vasospasm was significantly more likely to occur in women, those patients with a history of hypertension, those in whom a larger amount of SAH was observed on the admission CT scan, and patients with IVH, hydrocephalus, larger aneurysms, and poorer neurological grades, except for a reduced risk in patients in WFNS Grade V. The reduced risk of vasospasm in patients in WFNS Grade V may represent an artifact due to early death in that group before the development of vasospasm. Treatment variables associated with vasospasm included use of anticonvulsant medications, use of phenytoin, and implementation of prophylactic hemodilution, hypervolemia, or induced hypertension. Hemodilution, hypervolemia, and induced hypertension, which were used therapeutically in patients in whom vasospasm was diagnosed, were not analyzed in either a univariate or a multivariate analysis because their use did not precede the occurrence of vasospasm. The patient' s race, presence of intracerebral hematoma, location of the ruptured aneurysm, admission temperature, admission diastolic blood pressure, use of phenobarbital, whether surgery was performed, time to surgery, and time to development of vasospasm had no significant relation to the development of vasospasm.
Several multivariate analyses were performed in which variables found to be significant in the univariate analysis were included. Results of the final model that was fitted are shown in Table 4 . Continuous variables were entered in categorical or dichotomous forms. The analysis was adjusted for the study and tirilazad dose to control for differences among studies and to study drug effects. For all patients, vasospasm was significantly predicted by age, again showing an inverted U-shaped relationship with a peak incidence among patients 40 to 59 years of age. Other significant variables were history of hypertension, neurological grade, blood clot thickness, aneurysm size, presence of IVH, prophylactic induced hypertension, and the particular study in which the patient participated. The GCS score was dropped from the multivariate analysis because of its high correlation with the neurological (WFNS) grade. In the two studies in which both men and women participated, sex was not a significant predictor. Women entered into the highdose study in North America had a significantly higher risk of vasospasm, compared with other studies. Tirilazad dose was not a significant predictor.
An additional analysis was performed using only those patients with WFNS grades between I and III. Similar analyses were also conducted separately on patients in the first two studies 13, 18 and on those patients-all female-who were included in the third and fourth studies (data not shown). 21, 22 It was statistically valid to analyze data from placebo-and drug-treated patients because, as noted earlier, drug treatment was not a significant predictor of vasospasm in the univariate analysis. The multivariate analysis of the separate sets of studies found minor differences from the analysis of the entire data set. Age was not significant in the women-only studies, IVH was not significant in either subset, and aneurysm size was not significant in the two early studies.
The results of univariate analysis of factors associated with vasospasm for good-grade patients are shown in Table  3 . The multivariate analysis showed that factors significantly associated with vasospasm among all good-grade patients included patient age, history of hypertension, clinical grade on admission, clot thickness, presence of IVH, aneurysm size, use of prophylactic induced hypertension, and the particular study in which the patient participated (Table  4) . These factors as well as their effects were very similar to those obtained from the analysis of the entire database. The incidence of vasospasm in relation to patient age and sex was examined to determine whether menopausal status influenced vasospasm. Interestingly, the inverted U-shaped relationship between vasospasm and age was confined to women, with older women having similar risk to younger ones, who would likely be premenopausal, suggesting no effect of menopause on vasospasm.
Discussion
This is the largest, comprehensive multivariate statistical analysis in which an attempt has been made to determine factors associated with the development of vasospasm. It demonstrates that vasospasm, as defined by its clinical characteristics and backed by radiological and laboratory investigations that exclude other causes of neurological deterioration, varies with the age of the patient, presence of preexisting hypertension, neurological grade, amount of subarachnoid blood on the admission CT scan, presence of IVH, aneurysm size, and whether the patient is being treated with prophylactic induced hypertension. The rate of vasospasm also varied somewhat across the four trials. Authors of previous studies have attempted to identify factors that predict vasospasm, but many did not recognize the importance of using multivariate statistical analysis to identify factors of independent importance. 25 Some investigations were limited by a lack of this type of analysis, by inclusion of only small numbers of patients, and by inclusion of only some factors possibly predictive of vasospasm. 32 
Patient Age and Vasospasm
Of 10 studies in which multivariate analysis was used, six found that age did not influence vasospasm, 5, 7, 16, 24, 30, 32 two found that vasospasm was more likely in younger patients 6,33 and two did not include the patient' s age in the (Table 5) . 1, 15 The effect of age and other variables on outcome and vasospasm in 906 patients entered into a randomized trial of nicardipine was assessed. 23 Increasing age was an independent adverse factor for outcome and was associated with an increased risk of symptomatic vasospasm. Angiographic vasospasm, however, did not change with age. The results of the present study indicate that age itself independently affects susceptibility to symptomatic vasospasm. The relationship was an inverted U-shaped curve with risk peaking between the ages of 40 and 59 years. Authors of previous studies may not have identified this association because age was analyzed as a continuous variable. The variation in the incidence of vasospasm that was associated with age likely reflects the interplay of agerelated loss of compensatory mechanisms to sustain cerebral blood flow in the setting of vasospasm; 8, 23, 27, 28, 37 the increased risk of medical complications in the elderly, which might increase the likelihood that infarction may develop as a result of vasospasm or which might lead to a neurological deterioration that could fit the definition of vasospasm used in these studies but, in reality, may be the result of multiple medical factors; 38 and the increased susceptibility of the aged brain to ischemia.
2,9,23

Hypertension and Vasospasm
In this study we demonstrated an adverse association between preexisting hypertension and vasospasm. In a previous multivariate analysis a relationship was identified between infarction observed on CT scans in patients with aneurysmal SAH and hypertension. 30 On the other hand, five other studies did not detect an effect of hypertension on the risk of vasospasm (Table 5) . [5] [6] [7] 16, 24 Hypertension may increase symptomatic vasospasm by increasing the susceptibility of the brain to ischemia. An argument favoring this is that both vasospasm and hypertension were predictors of ischemia in one study. 30 Possible mechanisms include hypertension-induced impairment in endothelium-dependent vasodilation and increase in arterial rigidity as well as reduction in neuronal reserve due to arteriolosclerosis-related neuronal loss. * The reference group consisted of men between 18 and 29 years of age with WFNS Grade I, no history of hypertension, no subarachnoid clot or IVH demonstrated on the admission CT scan, and an aneurysm that was 12 mm or smaller. These patients were not treated with prophylactic induced hypertension and were enrolled in the vehicle-treated group in the first study conducted in Europe, Australia, and New Zealand .
Neurological Grade and Vasospasm
Neurological grade was independently associated with vasospasm. There is a general relationship between the neurological grade and the amount of SAH on the CT scan. It would be expected, therefore, that patients in poorer neurological grades would experience more vasospasm because they would generally have more SAH. Multivariate analysis should correct for the association between the neurological grade and the CT grade because this analysis should only detect factors that are independently associated with vasospasm. The results of prior studies in which multivariate analysis was used are divided on the effect of neurological grade (Table 5 ). The explanation for the association is uncertain. It is unlikely that it is caused by a greater susceptibility of ill patients to the effects of cerebral ischemia from vasospasm or by a misdiagnosis of poor-grade patients because the relationship persisted even during the analysis of only good-grade patients.
31,34
Features on CT Scans and Vasospasm
This study confirms that the subarachnoid clot thickness or volume and the location of the aneurysm are the most powerful predictors of the development of vasospasm. 5, 11, 24, 35 Nine of 10 previous multivariate analyses confirmed that these factors are the most important predictors of vasospasm (Table 5) . 1, 5, 15, 30 This study differs from a prior analysis of some of the same patients 32 in that aneurysm location was not independently associated with vasospasm. Because vasospasm is best related to the volume and location of the SAH and because there is little evidence for variation in subarachnoid arterial responses to perivascular blood clot, 25 aneurysm location would not be expected to be independently associated with vasospasm. If the method of diagnosis was more likely to detect certain types of vasospasm, if some locations of vasospasm were more likely to be symptomatic, or if CT scanning was insensitive or inaccurate at detecting clot in some areas, then aneurysm location might add an independent predictive value.
Intraventricular hemorrhage was independently associated with vasospasm. Vasospasm has been reported in patients with IVH but only a minimal cisternal clot. 20, 26 In only two of six studies in which multivariate analysis was performed was IVH found to be associated with vasospasm after aneurysmal SAH (Table 5) . 1, 5, 15, 24, 32 We hypothesize that IVH is associated with vasospasm because it releases spasmogenic decaying blood into the subarachnoid space, but that this effect can only be demonstrated independently in large numbers of patients because it is relatively mild.
Additional Factors and Vasospasm
Additional factors associated with vasospasm in this study were ruptured aneurysm size, prophylactic induced hypertension, and the particular study in which the patient participated. Two prior multivariate analyses did not identify a relationship between aneurysm size and vasospasm, 7, 32 and the explanation for this association is unclear. The final factor identified in this study was that vasospasm was less likely to have occurred in patients entered into the first study of tirilazad. 18 This could represent a systematic diagnostic difference between investigators.
Limitations of This Analysis
Patients treated with tirilazad were compared with the vehicle-treated patients in the univariate analyses. The results could be affected if tirilazad reduced vasospasm; however, tirilazad had no effect on vasospasm in three studies 13, 18, 21 and reduced it only in one. 22 In addition, our multivariate analysis controlled for such treatment and, in any case, showed no independent effect of tirilazad treatment on vasospasm. It is of interest that there was an insignificant trend toward a lower risk of vasospasm and a higher tirilazad dose (ORs: 0.95 for 0.6 mg/kg/day, 0.94 for 2 mg/kg/ day, 0.88 for 6 mg/kg/day, and 0.75 for 15 mg/kg/day).
The study is limited to its assessment of factors included in the database and to the method of coding used for the data. 36 For example, raw data on aneurysm size were not available and, thus, aneurysm size had to be analyzed categorically. Clot clearance rate and density, cigarette smoking and various metabolic factors-some of which were found to predict development of vasospasm-could not be assessed ( Table 5 ). The results may not apply to patients undergoing endovascular treatment of aneurysms because these patients were not included in the database. It is important to emphasize that this analysis documents associations between various factors and symptomatic vasospasm. No conclusions can be drawn with regard to cause and effect. For example, the association between vasospasm and prophylactic induced hypertension could be due to any of these factors: 1) the treating physician correctly identified patients at increased risk of vasospasm and treated them accordingly; 2) the management strategy increased the risk of vasospasm; 3) there is some spurious statistical association; or 4) some combination of the other factors. Finally, the diagnosis of vasospasm was based on clinical and radiological criteria, but did not mandate the gold standard test, which is catheter angiography. The accuracy of this definition could be disputed, but it is noteworthy that in addition to new factors, our study has identified factors previously considered to be associated with vasospasm, suggesting that the data are valid, the method of diagnosis of vasospasm relatively accurate, and the new factors identified to be highly significant have some biological basis. It also is more difficult to diagnose clinical vasospasm in poor-grade patients. 34 In support of the accuracy of a vasospasm diagnosis, however, the analysis of all patients and that of goodgrade patients produced very similar results.
